ES2157872T1 - Compuestos y metodos para el tratamiento de la disenteria bacteriana usando antibioticos y composiciones de oligosacaridos que fijan las toxinas. - Google Patents

Compuestos y metodos para el tratamiento de la disenteria bacteriana usando antibioticos y composiciones de oligosacaridos que fijan las toxinas.

Info

Publication number
ES2157872T1
ES2157872T1 ES99906006T ES99906006T ES2157872T1 ES 2157872 T1 ES2157872 T1 ES 2157872T1 ES 99906006 T ES99906006 T ES 99906006T ES 99906006 T ES99906006 T ES 99906006T ES 2157872 T1 ES2157872 T1 ES 2157872T1
Authority
ES
Spain
Prior art keywords
oligosacarids
disenteria
toxins
antibiotics
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES99906006T
Other languages
English (en)
Inventor
David John Rafter
Robert Murray Ratcliffe
Bradley G Thompson
Glen D Armstrong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synsorb Biotech Inc
Original Assignee
Synsorb Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synsorb Biotech Inc filed Critical Synsorb Biotech Inc
Publication of ES2157872T1 publication Critical patent/ES2157872T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para impediro mejorar uno o más estados mediados por E. coli enterohemorrágica en un paciente que sufre de dicho estado o es susceptible al mismo, que comprende administrar simultáneamente al paciente una cantidad efectiva de al menos un antibiótico y una cantidad efectiva de al menos una secuencia de oligosacáridos de unión a SLT unida covalentemente a un soporte inerte farmacéuticamente aceptable (oligosacarídico-soporte), en el que dicha secuencia de oligosacárido se fija al SLT, y en el que el SLT unido al oligosacárido-soporte es capaz de eliminarse desde el tracto gastrointestinal.
ES99906006T 1998-02-23 1999-02-23 Compuestos y metodos para el tratamiento de la disenteria bacteriana usando antibioticos y composiciones de oligosacaridos que fijan las toxinas. Pending ES2157872T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7564398P 1998-02-23 1998-02-23

Publications (1)

Publication Number Publication Date
ES2157872T1 true ES2157872T1 (es) 2001-09-01

Family

ID=22127112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99906006T Pending ES2157872T1 (es) 1998-02-23 1999-02-23 Compuestos y metodos para el tratamiento de la disenteria bacteriana usando antibioticos y composiciones de oligosacaridos que fijan las toxinas.

Country Status (18)

Country Link
US (2) US6224891B1 (es)
EP (1) EP1056476A1 (es)
JP (1) JP2002503708A (es)
KR (1) KR20010032128A (es)
CN (1) CN1289254A (es)
AR (1) AR018104A1 (es)
AU (1) AU738081B2 (es)
BR (1) BR9907126A (es)
CA (1) CA2309943A1 (es)
DE (1) DE1056476T1 (es)
ES (1) ES2157872T1 (es)
GR (1) GR20010300029T1 (es)
IL (1) IL135976A0 (es)
NO (1) NO20004193D0 (es)
NZ (1) NZ504303A (es)
PL (1) PL342569A1 (es)
WO (1) WO1999042136A1 (es)
ZA (1) ZA991410B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869602B2 (en) * 2002-02-20 2005-03-22 The United States Of America As Represented By The Secretary Of The Army Method for treating, preventing, or inhibiting enterotoxigenic Escherichia coli infections with bovine red blood cells
US20060051440A1 (en) * 2002-09-10 2006-03-09 Joel Moss Factors that bind intestinal toxins
PL2076271T3 (pl) * 2006-10-02 2012-02-29 Friesland Brands Bv Hamowanie toksyn cholery przez galaktooligosacharydy (GOS)
WO2009023355A2 (en) * 2007-05-25 2009-02-19 Ironwood Pharmaceuticals, Inc. Compositions and methods for reducing the toxicity of certain toxins
GB201402267D0 (en) 2014-02-10 2014-03-26 Cambridge Entpr Ltd Antibacterial agents
BR112020000196A2 (pt) 2017-07-07 2020-07-07 Epicentrx, Inc. composições para administração parenteral de agentes terapêuticos
WO2019023320A1 (en) 2017-07-25 2019-01-31 Arizona Board Of Regents On Behalf Of Arizona State University FAST ANTIBIOTIC SENSITIVITY TESTING BY MONITORING THE SUBMICRON SCALE MOVEMENT OF SIMPLE BACTERIAL CELLS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4362720A (en) 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
US5079353A (en) 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
WO1993008209A1 (en) 1991-10-18 1993-04-29 Chembiomed Ltd. Diagnosis and treatment of bacterial dysentery
US5552294A (en) * 1992-10-20 1996-09-03 Children's Medical Center Corporation Rapid detection of virulence-associated factors
US5549895A (en) 1993-05-17 1996-08-27 Iowa State University Research Foundation, Inc. Method and colicin composition for inhibiting Escherichia coli 0157:H7 in food products
FR2747394B1 (fr) * 1996-04-15 1998-07-03 Rambach Alain Milieu de culture pour la mise en evidence des bacteries e. coli enterohemorragiques, et procede pour sa mise en evidence
CN1209752A (zh) * 1996-06-21 1999-03-03 辛索尔布生物技术有限公司 用于中和大肠杆菌毒素的寡糖的用途
US6063769A (en) 1996-11-14 2000-05-16 Synsorb Biotech, Inc. 1-thiogalactose derivatives
US5910579A (en) 1997-01-10 1999-06-08 Synsorb Biotech Inc. Processes for the preparation of αGal(1->4)βGal (1->4) Glc-OR

Also Published As

Publication number Publication date
KR20010032128A (ko) 2001-04-16
BR9907126A (pt) 2000-10-03
CA2309943A1 (en) 1999-08-26
IL135976A0 (en) 2001-05-20
GR20010300029T1 (en) 2001-08-31
NO20004193L (no) 2000-08-22
AR018104A1 (es) 2001-10-31
NO20004193D0 (no) 2000-08-22
PL342569A1 (en) 2001-06-18
WO1999042136A1 (en) 1999-08-26
US6224891B1 (en) 2001-05-01
NZ504303A (en) 2002-08-28
CN1289254A (zh) 2001-03-28
AU2606899A (en) 1999-09-06
AU738081B2 (en) 2001-09-06
ZA991410B (en) 1999-10-06
EP1056476A1 (en) 2000-12-06
JP2002503708A (ja) 2002-02-05
US20010018065A1 (en) 2001-08-30
DE1056476T1 (de) 2001-08-23

Similar Documents

Publication Publication Date Title
AU2001259306A1 (en) Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
DK0759774T3 (da) Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
EA200100623A1 (ru) Кетолидные антибиотики
BR9602630A (pt) Acido7-([1alfa,5alfa,6alfa])-6-amino-3-azabiciclo[3.1.0.]hex-3-il)-6-flúor-1-(2,4-difluorofenil)-1,4-di-hidro-4-oxo-1,8-naftiridina-3-carboxílico, composção farmacêutica método de tratamento de uma infecção bacteriana e processo para a preparação do composto
RU99107569A (ru) Фармацевтические композиции, обладающие антимикробной активностью
ES2157872T1 (es) Compuestos y metodos para el tratamiento de la disenteria bacteriana usando antibioticos y composiciones de oligosacaridos que fijan las toxinas.
ATE556088T1 (de) Konjugat beinhaltend cephalosporin und glykopeptidantibiotikum
EP1057828A3 (en) Trovafloxacin oral suspensions
YU29504A (sh) Unakrsno vezani glikopeptidno-cefalosporinski antibiotici
WO2004096802A3 (en) ANTIBIOTIC TETRAHYDRO-β-CARBOLINE DERIVATIVES
BR9504119A (pt) Composto composiçao farmacêutica métodos para tratar uma infecçao bacteriana e uma infecçao micoplásmica
NO20042711L (no) Fremgangsmate for a behandle bakterielle infeksjoner ved anvendelse av gemifloksasin eller et salt derav et betalaktamantibiotikum
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
Mascarenhas Antibiotic prophylaxis in biliary surgery
DK0874863T3 (da) 3-deoxy-3-descladinose-derivater fra erythromycin A og B
WO1997049431A3 (en) Use of oligosaccharides for neutralising e. coli toxins
IT1313628B1 (it) Uso di compositi di fluorochinolone contro batteri dell'apparatorespiratorio
RU2000121246A (ru) Способ лечения язвенной болезни двенадцатиперстной кишки
NZ332434A (en) Use of oligosaccharide compositions which bind one or more serotypes of cholerae toxin in the intestinal tract for the treatment of cholera and related conditions
NZ336216A (en) Compositions for treating gastroduodenal disorders comprising a pathogen